Corbus Pharmaceuticals appoints Winston Kung to Board, replaces exiting director Chip Catlin

Corbus Pharmaceuticals Holdings, Inc.

Avery 'Chip' Catlin resigned from Board and as Audit Chair effective Aug 15, 2024; no disagreement with company.
Winston W. Kung, age 49, appointed to Board effective Aug 16, 2024; will serve as Audit Committee Chair.
Kung is CFO of ArriVent BioPharma; previously COO/CFO at PMV Pharma, VP at Celgene, and roles at Citigroup and Lehman.
Kung receives initial option grant for 5,566 shares and 5,566 RSUs; annual cash retainer $40,000 plus $20,000 for Audit Chair.

item 5.02 item 7.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Winston W. Kung

Director

CRBP · Corbus Pharmaceuticals Holdings, Inc.

Effective: 2024-08-16
Filed: August 20, 2024, 7:59 PM ET

Effective August 16, 2024, the Board, upon the recommendation of the Nominating and Corporate Governance Committee of the Board, appointed Winston W. Kung, age 49, to serve as a member of the Board.

Departed

Avery W. Catlin

Director

CRBP · Corbus Pharmaceuticals Holdings, Inc.

Effective: 2024-08-15
Successor: Winston W. Kung
Filed: August 20, 2024, 7:59 PM ET

On August 15, 2024, Avery W. Catlin submitted his resignation from the Board of Directors (the “Board”) of Corbus Pharmaceuticals Holdings, Inc. (the “Company”), effective as of August 15, 2024.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Winston W. Kung was appointed as Director at Corbus Pharmaceuticals Holdings, Inc..

Action: appointed
Role: Director

Exact text from the filing

Effective August 16, 2024, the Board, upon the recommendation of the Nominating and Corporate Governance Committee of the Board, appointed Winston W. Kung, age 49, to serve as a member of the Board.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Avery W. Catlin resigned as Director at Corbus Pharmaceuticals Holdings, Inc..

Action: resigned
Role: Director

Exact text from the filing

On August 15, 2024, Avery W. Catlin submitted his resignation from the Board of Directors (the “Board”) of Corbus Pharmaceuticals Holdings, Inc. (the “Company”), effective as of August 15, 2024.

View on SEC.gov

Corbus Pharmaceuticals Holdings, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-24-098861

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.